On the assumption they are confident that they will get approval in March, a second more substantial capital raising for FDA funding would make more sense.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025